SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Bayer Shares Post Hoc Analysis of Lynkuet Sleep Outcomes

Bayer said it presented a post hoc sub-analysis of key secondary endpoint data from the OASIS-1 and OASIS-2 pivotal trials for Lynkuet (elinzanetant) at the 2026 Menopause Society Annual Meeting.

BAYN

Related stories